

We claim:

1. A method for determining active plasminogen activator inhibitor-Type 1 (PAI-1) in a biological fluid, the method comprising the steps of:
  - 5 (i) providing a sample of a biological fluid; and
  - (ii) measuring the amount of PAI-1/multimeric vitronectin complex in the sample to determine active PAI-1 in the sample.
2. The method of claim 1 wherein step (ii) comprises the steps of:
  - 10 (a) contacting the sample either simultaneously or stepwise with a first antibody which binds selectively to PAI-1 and a labelled second antibody which binds selectively to multimeric vitronectin; and
  - (b) determining the second antibody bound to the complex to  
15 measure the amount of PAI-1/multimeric vitronectin complex in the sample.
3. The method of claim 1 wherein step (ii) comprises the steps of:
  - 20 (a) contacting the sample either simultaneously or stepwise with a first antibody which binds selectively to multimeric vitronectin and a labelled second antibody which binds selectively to PAI-1; and
  - (b) determining the second antibody bound to the complex to  
25 measure the amount of PAI-1/multimeric vitronectin complex in the sample.
4. The method of claim 1 wherein step (ii) comprises the steps of:
  - 30 (a) contacting the sample either simultaneously or stepwise with a first antibody which binds selectively to PAI-1 and a labelled second antibody which binds selectively to multimeric vitronectin;
  - (b) separating the PAI-1/multimeric vitronectin/first antibody/second

- antibody complex formed in step (a) from the sample; and
- (c) determining the second antibody bound to the complex to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

5

5. The method of claim 1 wherein step (ii) comprises the steps of:
- (a) contacting the sample either simultaneously or stepwise with a first antibody which binds selectively to multimeric vitronectin and a labelled second antibody which binds selectively to PAI-1;
- 10 (b) separating the PAI-1/multimeric vitronectin/first antibody/second antibody complex formed in step (a) from the sample; and
- (c) determining the second antibody bound to the complex to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

15

6. The method of claim 1 wherein step (ii) comprises the steps of :
- (a) simultaneously contacting the sample with a first antibody which binds selectively to PAI-1, the first antibody being immobilised on a solid support, and with a labelled second antibody which binds selectively to multimeric vitronectin ; and
- 20 (b) determining the second antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

20

- 25 7. The method of claim 1 wherein step (ii) comprises the steps of :
- (a) contacting the sample with a first antibody which binds selectively to PAI-1, the first antibody being immobilised on a solid support;
- (b) contacting the solid support with a labelled second antibody which binds selectively to multimeric vitronectin ; and
- 30 (c) determining the second antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in

30

11. The method of claim 1 wherein step (ii) comprises the steps of:
- (a) contacting the sample with a first antibody which binds selectively to multimeric vitronectin, the first antibody being immobilised on a solid support;
  - (b) contacting the solid support with a second antibody which binds selectively to PAI-1;
  - (c) contacting the solid support with a labelled third antibody which binds selectively to the second antibody; and
  - (d) determining the third antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.
12. The method of claim 1 wherein step (ii) comprises the steps of:
- (a) contacting the sample, either simultaneously or stepwise, with a first antibody which binds selectively to PAI-1 and to which is attached one member of a capture pair and with a labelled second antibody which binds selectively to multimeric vitronectin to form a mixture;
  - (b) contacting the mixture with a solid support on which is immobilised the other member of the capture pair; and
  - (c) determining the second antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.
13. The method of claim 1 wherein step (ii) comprises the steps of:
- (a) contacting the sample either simultaneously or stepwise, with a first antibody which binds selectively to multimeric vitronectin and to which is attached one member of a capture pair and with a labelled second antibody which binds selectively to PAI-1 to form a mixture;
  - (b) contacting the mixture with a solid support on which is

21. The method of any one of claims 1 to 15 wherein the second antibody is labelled with a luminescent material.

22. The method of claim 21 wherein the luminescent material is selected from the group consisting of a cyclic diacyl hydrazide, luminol, isoluminol, an acridinium ester, a pyridopyridazine, a dioxerane, a bioluminescent protein and a luciferase.

23. The method of any one of claims 1 to 15 wherein the second antibody is labelled with a label selected from the group consisting of a metal complex, a stable free radical, a vesicle, a liposome, a colloidal particle, a latex particle, a spin label and biotin/avidin.

24. The method of any one of claims 6 to 13 wherein the solid support is selected from the group consisting of an ELISA plate, a polyacrylamide matrix, a polystyrene tube, polystyrene beads, latex particles, paramagnetic particles, acrylic particles and gelatin particles.

25. A kit for determining active PAI-1 in a biological fluid comprising:  
(a) a first antibody which binds selectively to PAI-1; and  
(b) a labelled second antibody which binds selectively to multimeric vitronectin.

26. A kit for determining active PAI-1 in a biological fluid comprising:  
(a) a first antibody which binds selectively to multimeric vitronectin; and;  
(b) a labelled second antibody which binds selectively to PAI-1.

27. The kit of claim 25 or 26 wherein said first antibody is immobilised on a solid support.